Phase II trial of Transarterial Chemoembolization using Drug-eluting bead for advanced HCC refractory to Lipiodol-TACE
Phase 2
- Conditions
- advanced hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000015463
- Lead Sponsor
- Clinical Research Group of the Japanese Society for Transcatheter Hepatic Arterial Embolization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
1) after HCC rupture 2) Reconstruction of the biliary tract history 3) severe ascites or pleural effusion 4) severe arterioportal shunt or arteriovenous shunt 5) Severe complication (Cardiac failure, Myocardial infarction, Pulmonary fibrosis, Interstitial pneumonia, Uncontrollable diabetic, Renal failure) 6) development of collateral feeding artery 7) Pregnant, nursing or possible pregnant woman 8) Heparic artery occlusion under CT angiography or angiography (Registration after qualification with CT angiography. Judging occlusion under angiography, including reservoir DAS, in case unqualified judgement with CT angiography) 9) Qualified ineligible patients being this clinical trial by responsible doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate (1 months)
- Secondary Outcome Measures
Name Time Method adverse events, progression-free survival, overall survival